HLA B62 as a possible risk factor for drug reaction with eosinophilia and systemic symptoms to piperacillin/tazobactam

J Allergy Clin Immunol Pract. 2017 May-Jun;5(3):829-830. doi: 10.1016/j.jaip.2016.10.008. Epub 2016 Nov 30.

Authors

Krzysztof Rutkowski¹, Craig Taylor², Annette Wagner³

Affiliations

¹ Department of Allergy, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom. Electronic address: chris.rutkowski@gstt.nhs.uk.
² Tissue Typing Laboratory, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.
³ Department of Allergy, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.

PMID: 27914818
DOI: 10.1016/j.jaip.2016.10.008

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Allergens / immunology
Allergens / therapeutic use*
Drug Hypersensitivity Syndrome / genetics*
Female
HLA-B Antigens / genetics*
Histocompatibility Testing
Humans
Hypersensitivity, Delayed
Male
Middle Aged
Piperacillin / immunology
Piperacillin / therapeutic use*
Risk Factors
Skin Tests
Tazobactam / immunology
Tazobactam / therapeutic use*

Substances

Allergens
HLA-B Antigens
Tazobactam
Piperacillin